LLYEli Lilly and CompanyRunning, no new patients
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 463 (final count)
- Started
- Dec 5, 2016
- Main results expected
- Mar 29, 2019
- Fully finished
- Mar 2028
- Results posted
- Mar 30, 2020
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) (Abemaciclib + NSAI & Placebo NSAI)
Measured over: Randomization to Measured Progressive Disease or Death (up to 26 Months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02763566 · record last updated 2026-02-05 · checked 2026-11-09 15:42 UTC